(1) Terrible Earnings: CLVS existence is off of investor's money. With an negative $10 earnings on a $13 per share price tag, CLVS is burning through investor's cash at an astronomical rate
(2) Putting all your eggs in one basket is bad strategy- CLVS have only one (yes..one) viable product in the pipeline. If FDA rejects, it's either Chapter 11 or major stock dilution. Risk does not justify benefit
(3) No near term catalyst- No partnerships in sight, no FDA approval in site, no acquisitions in site. It's like a sail boat with no wind. Dead in the water while burning through cash.
(4) Smart money is exiting- Net change within the last quarter in institutional held shares is -20%. If the big boys are heading toward the exit in an orderly fashion, why I am entering a burning building? Even management is not holding on to their shares with dumping 34K shares last quarter.
(5) CLVS was basically a fly on the wall at ASCO. That's pretty bad.
Not sure what I was thinking when I bought CLVS....... possibly irrational Greed.
IMGN management have no ownership in IMGN and uses IMGN as an ATM (withdrawals only). Historical chart shows you each time IMGN gains traction, shareholders value gets diluted with new stocks being issues and in this case new notes issued (IOUs). IMGN management have milked investors capital with false hopes of developing their own drug while their only source of revenue stream is paltry royalties. With the current stock price around $3 and earnings per share -$2, IMGN management have pretty much milked IMGN to the ground. IMGN CEO should be whipped and thrown out of management. If you enjoy making a donation to support extravagant life styles of CEOs, IMGN is for you.